Tris Pharma
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Tris Pharma sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Tris Pharma: 14 sponsored US clinical trials, none currently recruiting.
Tris Pharma sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 6 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Neuropathies, with 1 trials.
Top-decile sponsor footprint
Tris Pharma ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
NCT06545097
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
NCT06423703
A Study to Assess the Abuse Potential of Intranasal Cebranopadol
NCT06453265
Assessment of Abuse Potential of Cebranopadol in Humans
NCT05256108
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT04027361
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
NCT03834766
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
NCT03610464
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
NCT03088267
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT02083783
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
NCT01939366
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
NCT03958123
A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol
NCT03882762
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
NCT01709214
Bunionectomy Trial With GRT6005
NCT00872885
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Therapeutic Areas
How the Tris Pharma archive is shaped
14 indexed studies, none listed as recruiting (0% open); 14 completed (100%).
Phase mix: 6 late (III/IV) vs 8 early (I/II) (balanced across stages).
Top condition: Diabetic Neuropathies (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Tris Pharma: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Tris Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Tris Pharma page
14 registered trials is a research-attention snapshot, not an endorsement of Tris Pharma or any single study.
- None of Tris Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Diabetic Neuropathies is the condition Tris Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Neuropathies trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tris Pharma pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.